Arq. Bras. Cardiol. 2020; 115(2): 292-301
Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) – 2020
Alexandre de Matos Soeiro
, Tatiana de Carvalho Andreucci Torres Leal, Marcel de Paula Pereira, Eduardo Gomes Lima, Ana Cristina Baptista da Silva Figueiredo, João Luiz Fernandes Petriz
, Dalton Betolim Precoma
, Carlos Vicente Serrano Jr
1. Introduction
The new coronavirus (SARS-CoV-2) pandemic has led to debate about the best treatment for the disease and its complications. Recent publications have shown that cardiovascular disease is among the main risk factors for disease progression, including high blood pressure and diabetes mellitus. –
It has been demonstrated that patients infected with the new coronavirus (COVID-19) have distinct activation of prothrombotic mechanisms, including a greater likelihood of thrombotic events. Acute coronary syndrome (ACS) with or without ST-elevation can occur in patients with COVID-19, although the actual incidence is still uncertain. – Thus, several issues related to using antiplatelet agents and anticoagulants in patients with suspected or confirmed COVID-19 infection remain uncertain. The following recommendations are valid for the most diverse clinical situations, such as atrial fibrillation, acute coronary syndrome, chronic coronary artery disease, percutaneous coronary intervention, post-cardiac surgery, ischemic stroke, and venous thromboembolism, and should be applied on a case-by-case basis.
[…]
4,222
